Format

Send to

Choose Destination
Int J Parasitol Drugs Drug Resist. 2012 Jan 28;2:11-9. doi: 10.1016/j.ijpddr.2012.01.003. eCollection 2012 Dec.

Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?

Author information

1
Center for Neglected Diseases Drug Discovery (CND3), Institut Pasteur Korea, Seongnam-si, Gyeonggi-do, South Korea.
2
Drugs for Neglected Diseases initiative (DND i ), 15 Chemin Louis Dunant, Geneva 1202, Switzerland.

Abstract

Leishmaniasis is one of the most neglected tropical disease in terms of drug discovery and development. Most antileishmanial drugs are highly toxic, present resistance issues or require hospitalization, being therefore not adequate to the field. Recently improvements have been achieved by combination therapy, reducing the time and cost of treatment. Nonetheless, new drugs are still urgently needed. In this review, we describe the current visceral leishmaniasis (VL) treatments and their limitations. We also discuss the new strategies in the drug discovery field including the development and implementation of high-throughput screening (HTS) assays and the joint efforts of international teams to deliver clinical candidates.

KEYWORDS:

Drug discovery; High throughput screening; Leishmania; Leishmaniasis

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center